Latest On Heron Therapeutics, Inc (HRTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-13 00:29 EST | News | Heron stock slumps ~35% amid quarterly misses on both lines | N/A |  |
| 2023-05-12 10:15 EST | News | Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-11 20:40 EST | News | Heron Therapeutics GAAP EPS of -$0.27 misses by $0.07, revenue of $29.62M misses by $0.07M | N/A | |
| 2023-05-11 05:36 EST | News | Heron Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-21 21:15 EST | News | Cleaning The House May Not Solve Heron Therapeutics' Problems | N/A | |
About Heron Therapeutics, Inc (HRTX):
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emeto read more...genic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
General
- Name Heron Therapeutics, Inc
- Symbol HRTX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 223
- Last Split Factor1:20
- Last Split Date2014-01-13
- Fiscal Year EndDecember
- IPO Date1987-08-26
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.herontx.com
Valuation
- Price/Sales (Trailing 12 Mt.) 16.77
- Price/Book (Most Recent Quarter) 6.33
- Enterprise Value Revenue 14.82
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.07
- Next Year EPS Estimate -$1.08
- Next Quarter EPS Estimate -$0.54
- Profit Margin -256%
- Operating Margin -251%
- Return on Assets -32%
- Return on Equity -71%
- Revenue 88.64 million
- Earnings Per Share -$2.56
- Revenue Per Share $0.98
- Gross Profit -120884000
- Quarterly Earnings Growth -41.3%
Highlights
- Market Capitalization 1.43 billion
- EBITDA -205512000
- PEG Ratio -0.18
- Analyst Target Price $34
- Book Value Per Share $2.59
Share Statistics
- Shares Outstanding 91.4 million
- Shares Float 79.79 million
- % Held by Insiders 29%
- % Held by Institutions 101.43%
- Shares Short 20.15 million
- Shares Short Prior Month 19.71 million
- Short Ratio 21.47
- Short % of Float 27%
- Short % of Shares Outstanding 22%
Technicals
- Beta 1.45
- 52 Week High $22.4
- 52 Week Low $10.74
- 50 Day Moving Average 18.15
- 200 Day Moving Average 17.33
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Heron Therapeutics, Inc (HRTX) Dividend Calendar:
Heron Therapeutics, Inc (HRTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Heron Therapeutics, Inc (HRTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Heron Therapeutics, Inc (HRTX) Chart:
Heron Therapeutics, Inc (HRTX) News:
Below you will find a list of latest news for Heron Therapeutics, Inc (HRTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Heron Therapeutics, Inc (HRTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest HRTX Trades:
Heron Therapeutics, Inc (HRTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-20 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-15 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 8-K (Current report) | |
| 2020-09-28 | 8-K (Current report) | |
| 2020-09-16 | 8-K (Current report) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-07-24 | 8-K (Current report) | |
| 2020-07-16 | 8-K (Current report) | |
| 2020-07-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
Heron Therapeutics, Inc (HRTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Heron Therapeutics, Inc (HRTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 29%
Institutional Ownership: 10143%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-01 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 1,158.00 | 13.97 | 16,175.75 | 0.00 | |
| 2019-11-29 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 24,000.00 | 26.00 | 624,000.00 | 0.00 | |
| 2019-11-29 | KIMBERLY MANHARD | Executive VP, Drug Development | Buy | 24,000.00 | 13.00 | 312,000.00 | 24,000.00 | |
| 2019-10-04 | KEVIN C TANG | Director | Buy | 285,714.00 | 17.50 | 4,999,995.00 | 5,799,810.00 | |
| 2019-10-03 | JOHN POYHONEN | EVP, Chief Commercial Officer | Buy | 5,143.00 | 17.50 | 90,002.50 | 18,143.00 | |
| 2019-10-03 | Barry D Quart | Chief Executive Officer | Buy | 4,571.00 | 17.50 | 79,992.50 | 94,652.00 | |
| 2019-05-22 | JOHN POYHONEN | Director | Buy | 3,000.00 | 17.55 | 52,650.00 | 13,000.00 | |
| 2019-05-15 | Waage Christian | Director | Buy | 1,400.00 | 18.04 | 25,261.74 | 1,400.00 | |
| 2019-05-01 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 1,109.00 | 18.86 | 20,918.07 | 0.00 | |
| 2018-11-02 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 494.00 | 30.62 | 15,124.95 | 0.00 | |
| 2018-10-01 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 6,000.00 | 32.07 | 192,433.20 | 0.00 | |
| 2018-10-01 | KIMBERLY MANHARD | Executive VP, Drug Development | Buy | 6,000.00 | 13.00 | 78,000.00 | 6,000.00 | |
| 2018-09-14 | Barry D Quart | Chief Executive Officer | Buy | 19,675.00 | 7.20 | 141,660.00 | 89,275.00 | |
| 2018-09-12 | KEVIN C TANG | Director | Sell | 2,695,000.00 | 35.75 | 96,346,250.00 | 5,830,215.00 | |
| 2018-07-02 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 100.00 | 38.85 | 3,885.00 | 0.00 | |
| 2018-07-02 | KIMBERLY MANHARD | Executive VP, Drug Development | Sell | 5,900.00 | 37.51 | 221,293.66 | 100.00 | |
| 2018-07-02 | ROBERT HOFFMAN | CFO & SVP, Finance | Sell | 1,060.00 | 38.80 | 41,123.02 | 1,280.00 | |
| 2018-07-02 | ROBERT HOFFMAN | CFO & SVP, Finance | Sell | 28,940.00 | 38.15 | 1,104,107.30 | 2,340.00 | |
| 2018-07-02 | Robert Rosen | President | Sell | 3,400.00 | 38.75 | 131,764.96 | 2,640.00 | |
| 2018-07-02 | ROBERT HOFFMAN | CFO & SVP, Finance | Buy | 30,000.00 | 15.30 | 459,000.00 | 31,280.00 | |